Clinical Trials
9 trialsNCT02213913 2026-03-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Phase 1/2 Completed
NCT01542918 2020-08-11
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT01326702 2019-12-16
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00867529 2018-01-02
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00072514 2017-06-29
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00720135 2015-06-08
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT00221325 2015-02-16
A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT00416923 2015-02-16
Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT00054639 2014-05-28
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed